Relating to modification of certain prescription drug benefits and coverage offered by certain health benefit plans.
Impact
If enacted, HB 826 would bolster patient protections regarding prescription drug coverage by ensuring that enrollees can maintain their current drug benefits as long as their conditions persist and prescriptions continue to be deemed the most appropriate course of treatment by their healthcare providers. This means that issuers cannot remove drugs from formularies or impose new limitations such as requiring prior authorizations without prior notification ahead of the renewal date. The effective date for these changes is outlined as January 1, 2024, which indicates a phased implementation of the new rules.
Summary
House Bill 826 aims to amend existing provisions in the Texas Insurance Code regarding modifications that health benefit plans can make to prescription drug coverage. The bill stipulates that health benefit plan issuers are prohibited from modifying an enrollee's contracted benefit level for any prescription drug that was approved or covered in the previous plan year, provided the enrollee remains under that plan. Changes instituted at the time of coverage renewal must be communicated to enrollees and various stakeholders, enhancing transparency in the modification process.
Sentiment
The general sentiment surrounding HB 826 appears to favor increased protections for patients against potentially arbitrary changes in their prescription drug coverage by health insurers. Stakeholders, particularly advocacy groups representing patients and healthcare providers, have likely voiced support for this bill, seeing it as a step towards enhancing both stability and predictability in the coverage of essential medications without unexpected cost increases or accessibility issues.
Contention
While the bill is generally well-received, some concerns have been raised about the potential implications for plan issuers and the balance between regulatory oversight and the flexibility needed for insurers to manage their formularies effectively. Critics argue that overly stringent regulations could lead to unintended consequences, such as increased costs for issuers, which may ultimately be passed down to consumers in the form of higher premiums. As such, the legislation highlights an ongoing debate about the extent and limits of regulation in the healthcare insurance sector.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.